Process Intensification Beyond mAbs: Advancing Perfusion Manufacturing For Cell & Gene Therapies
Upstream intensification and perfusion changed the economics of monoclonal antibody manufacturing, bringing higher productivity, better facility utilization, and lower cost of goods. Cell and gene therapy developers are now adapting those same approaches. Low yields, scale-up limits, process variability, and economic pressure remain common obstacles across lentiviral vector production, CAR-T and NK cell therapies, and iPSC-based platforms. How far the mAb experience carries over to these modalities is the open question. Recent case studies inform the discussion, which looks at perfusion culture, advanced cell retention technologies, and emerging process analytical technology (PAT) capabilities designed to support next-generation cell therapy manufacturing.
Watch to see how mAb process intensification is being applied to cell and gene therapy production.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.